ArticleAnnals of vascular surgery2026
Five Year Outcomes after Fenestrated Endovascular Aortic Repair in Octogenarians.
Article in Annals of vascular surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundElderly patients are prone to complications in aortic surgery. Fenestrated endovascular aortic repair (FEVAR) can be used to treat complex abdominal aortic aneurysms (AAAs). We describe 5-year results with FEVAR using the Zenith Fenestrated device (ZFEN) in an elderly population.
methodsThis is a retrospective review of all FEVARs between January 2012 and August 2019 at a tertiary academic medical center. The study compared 60-month outcomes for patients younger than 79.9 (Group 1) and greater than 80.0 years (Group 2). The primary outcome was mortality. Secondary outcomes included reintervention and complications.
results153 patients met inclusion criteria, 27 of whom were age ≥80.0 years and were included in Group 2. Group 1 had more active smokers at surgery (50.0% vs. 18.5%, P = 0.003) and higher body mass index (29.0 ± 6.1 vs. 25.4 ± 3.4, P = 0.004). The remaining baseline comorbid conditions and medications did not differ between groups. Length of stay (3.5 vs. 3.7 days, P = 0.88) and need for facility discharge did not differ (10.3% vs. 7.4%, P = 0.13). At 60 months, the estimated overall survival was not different between groups (66.7% Group 2 vs. 73.8% Group 1, P = 0.55). Estimated freedom from reintervention also did not differ at 60 months (81.5% Group 2 vs. 72.2% Group 1, P = 0.16).
conclusionFEVAR with ZFEN is safe and effective for the treatment of complex AAA in patients older than 80 years. Five-year outcomes, overall survival, and complications did not differ between groups, suggesting benefit of performing elective aneurysm repair in well selected elderly patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.